StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Protagonist Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $59.88M, up 140.8% year over year. For fiscal 2025 it was -$156.85M, down 161.8% from the year before. The highest annual figure on record is $253.67M in fiscal 2024.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$156.85M-161.8%
FY2024Dec 31, 2024$253.67M–
FY2023Dec 31, 2023-$92.68M–
FY2022Dec 31, 2022-$130.34M–
FY2021Dec 31, 2021-$125.03M–
FY2020Dec 31, 2020-$63.57M–
FY2019Dec 31, 2019-$79.79M–
FY2018Dec 31, 2018-$41.74M–
FY2017Dec 31, 2017-$37.49M–
FY2016Dec 31, 2016-$32.35M–
FY2015Dec 31, 2015-$14.55M–
FY2014Dec 31, 2014-$9.06M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$159.16M–
Q1 FY2026Mar 31, 2026-$3.24M–
Q4 FY2025Dec 31, 2025-$49.98M-139.4%
Q3 FY2025Sep 30, 2025-$46.06M–
Q2 FY2025Jun 30, 2025-$41.74M–
Q1 FY2025Mar 31, 2025-$19.07M-109.2%
Q4 FY2024Dec 31, 2024$126.90M+444.7%
Q3 FY2024Sep 30, 2024-$41.22M–
Q2 FY2024Jun 30, 2024-$38.55M–
Q1 FY2024Mar 31, 2024$206.55M–
Q4 FY2023Dec 31, 2023$23.30M–
Q3 FY2023Sep 30, 2023-$38.08M–
Q2 FY2023Jun 30, 2023-$42.12M–
Q1 FY2023Mar 31, 2023-$35.77M–
Q4 FY2022Dec 31, 2022-$36.26M–
Q3 FY2022Sep 30, 2022-$32.03M–
Q2 FY2022Jun 30, 2022-$41.18M–
Q1 FY2022Mar 31, 2022-$20.86M–
Q2 FY2021Jun 30, 2021-$30.70M–
Q1 FY2021Mar 31, 2021-$23.84M–
Q4 FY2020Dec 31, 2020-$18.48M–
Q3 FY2020Sep 30, 2020-$7.59M–
Q2 FY2020Jun 30, 2020-$18.02M–
Q1 FY2020Mar 31, 2020-$19.48M–
Q4 FY2019Dec 31, 2019-$17.07M–
Q3 FY2019Sep 30, 2019-$16.97M–
Q2 FY2019Jun 30, 2019-$31.23M–
Q1 FY2019Mar 31, 2019-$14.52M–
Q4 FY2018Dec 31, 2018-$15.28M–
Q3 FY2018Sep 30, 2018-$9.24M–
Q2 FY2018Jun 30, 2018-$9.07M–
Q1 FY2018Mar 31, 2018-$8.15M–
Q4 FY2017Dec 31, 2017-$3.40M–
Q3 FY2017Sep 30, 2017-$4.87M–
Q2 FY2017Jun 30, 2017-$15.04M–
Q1 FY2017Mar 31, 2017-$14.19M–
Q4 FY2016Dec 31, 2016-$11.32M–
Q3 FY2016Sep 30, 2016-$7.06M–

More Protagonist Therapeutics figures

See a number that looks wrong?